The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
分析師的判決：14位專家眼中的細胞內療法
Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:ITCI) in the last three months.
在過去三個月中，有14位分析師公佈了對細胞內療法（納斯達克股票代碼：ITCI）的評級，提供了從看漲到看跌的不同視角。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表簡要介紹了他們最近的收視率，展示了過去30天中不斷變化的情緒，並將其與前幾個月進行了比較。
In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $88.86, a high estimate of $103.00, and a low estimate of $77.00. Marking an increase of 10.55%, the current average surpasses the previous average price target of $80.38.
在對12個月目標股價的評估中，分析師公佈了對細胞內療法的見解，將平均目標價定爲88.86美元，最高估計爲103.00美元，低估值爲77.00美元。當前的平均價格上漲了10.55％，超過了之前的平均目標股價80.38美元。
Interpreting Analyst Ratings: A Closer Look
解讀分析師評級：仔細觀察
The...
通...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。